Alternative splicing and muscular dystrophy

RNA Biology

Volumn 7, Issue 4, 2010, Pages 441-452

  Pistoni, Mariaelena ^a   Ghigna, Claudia ^b   Gabellini, Davide ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c DULBECCO TELETHON INSTITUTE   (Italy)

Author keywords

Alternative splicing; Chromatin; Epigenetics; Facioscapulohumeral muscular dystrophy; Muscular dystrophy; Myotonic muscular dystrophy; Repetitive DNA

Indexed keywords

CUGBP1 PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; MBNL1 PROTEIN; MESSENGER RNA PRECURSOR; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; CLINICAL FEATURE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE SILENCING; HUMAN; MUSCLE FUNCTION; MYOTONIC DYSTROPHY; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; REVIEW; SKELETAL MUSCLE;

EUKARYOTA;

EID: 77957291654     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.7.4.12258     Document Type: Review

References (133)

1. Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009; 136:701-18.
2. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007; 8:749-61.
3. Wang Z, Burge CB. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 2008; 14:802-13.
4. Fu XD. Towards a splicing code. Cell 2004; 119:736-8.
5. Zhang XH, Chasin LA. Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 2004; 18:1241-50.
6. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10:741-54.
7. Licatalosi DD, Darnell RB. RNA processing and its regulation: global insights into biological networks. Nat Rev Genet 2010; 11:75-87.
8. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010; 463:457-63.
9. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The transcriptional landscape of the mammalian genome. Science 2005; 309:1559-63.
10. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40:1413-5.
11. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456:470-6.
12. Hillier LW, Reinke V, Green P, Hirst M, Marra MA, Waterston RH. Massively parallel sequencing of the polyadenylated transcriptome of C. elegans. Genome Res 2009; 19:657-66.
13. Stolc V, Gauhar Z, Mason C, Halasz G, van Batenburg MF, Rifkin SA, et al. A gene expression map for the euchromatic genome of Drosophila melanogaster. Science 2004; 306:655-60.
14. Castle JC, Zhang C, Shah JK, Kulkarni AV, Kalsotra A, Cooper TA, et al. Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat Genet 2008; 40:1416-25.
15. Ladd AN, Charlet N, Cooper TA. The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Mol Cell Biol 2001; 21:1285-96.
16. Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 1996; 76:371-423. (Pubitemid 26163713)
17. Cooper TA, Ordahl CP. A single cardiac troponin T gene generates embryonic and adult isoforms via developmentally regulated alternate splicing. J Biol Chem 1985; 260:11140-8.
18. 2+ binding associated with troponin T isoform switching in developing rabbit heart. Circ Res 1990; 66:1204-16.
19. Godt RE, Fogaca RT, Silva IK, Nosek TM. Contraction of developing avian heart muscle. Comp Biochem Physiol Comp Physiol 1993; 105:213-8.
20. Barreau C, Paillard L, Méreau A, Osborne HB. Mammalian CELF/Bruno-like RNA-binding proteins: molecular characteristics and biological functions. Biochimie 2006; 88:515-25. (Pubitemid 43867902)
21. Pascual M, Vicente M, Monferrer L, Artero R. The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. Differentiation 2006; 74:65-80. (Pubitemid 43376167)
22. Kuroyanagi H. Fox-1 family of RNA-binding proteins. Cell Mol Life Sci 2009.
23. Sawicka K, Bushell M, Spriggs KA, Willis AE. Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. Biochem Soc Trans 2008; 36:641-7.
24. Ryan KJ, Cooper TA. Muscle-specific splicing enhancers regulate inclusion of the cardiac troponin T alternative exon in embryonic skeletal muscle. Mol Cell Biol 1996; 16:4014-23.
25. Cooper TA. Muscle-specific splicing of a heterologous exon mediated by a single muscle-specific splicing enhancer from the cardiac troponin T gene. Mol Cell Biol 1998; 18:4519-25.
26. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998; 280:737-41.
27. Sugnet CW, Srinivasan K, Clark TA, O'Brien G, Cline MS, Wang H, et al. Unusual intron conservation near tissue-regulated exons found by splicing microarrays. PLoS Comput Biol 2006; 2:4.
28. Singh R, Valcarcel J, Green MR. Distinct binding specificities and functions of higher eukaryotic polypyrimidine tract-binding proteins. Science 1995; 268:1173-6.
29. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009; 136:777-93.
30. Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. Biochim Biophys Acta 2009; 1792:14-26.
31. Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 2005; 579:1900-3.
32. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003; 17:419-37.
33. Baralle D, Baralle M. Splicing in action: assessing disease causing sequence changes. J Med Genet 2005; 42:737-48.
34. Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 2004; 5:389-96. (Pubitemid 38529410)
35. Pagani F, Raponi M, Baralle FE. Synonymous mutations in CFTR exon 12 affect splicing and are not neutral in evolution. Proc Natl Acad Sci USA 2005; 102:6368-72. (Pubitemid 40617449)
36. Buratti E, Baralle FE. Influence of RNA secondary structure on the pre-mRNA splicing process. Mol Cell Biol 2004; 24:10505-14. (Pubitemid 39603113)
37. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. Nat Biotechnol 2004; 22:535-46.
38. Cookson W, Liang L, Abecasis G, Moffatt M, Lathrop M. Mapping complex disease traits with global gene expression. Nat Rev Genet 2009; 10:184-94.
39. Ghigna C, Valacca C, Biamonti G. Alternative splicing and tumor progression. Curr Genomics 2008; 9:556-70.
40. Emery AE. The muscular dystrophies. Lancet 2002; 359:687-95.
41. Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. Muscle Nerve 2000; 23:1456-71.
42. Wallace GQ, McNally EM. Mechanisms of muscle degeneration, regeneration and repair in the muscular dystrophies. Annu Rev Physiol 2009; 71:37-57.
43. Dahl KN, Ribeiro AJ, Lammerding J. Nuclear shape, mechanics and mechanotransduction. Circ Res 2008; 102:1307-18.
44. Abu-Baker A, Rouleau GA. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Biochim Biophys Acta 2007; 1772:173-85. (Pubitemid 46138035)
45. Tawil R. Facioscapulohumeral muscular dystrophy. Neurotherapeutics 2008; 5:601-6.
46. Wheeler TM. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics 2008; 5:592-600.
47. Ranum LP, Cooper TA. RNA-Mediated Neuromuscular Disorders. Annu Rev Neurosci 2006; 29:259-77.
48. Neguembor M, Gabellini D. In Junk We Trust: Repetitive DNA, Epigenetics and Facioscapulohumeral Muscular Dystrophy. Epigenomics 2010; 2:271-87.
49. Cho D, Tapscott S. Myotonic dystrophy: Emerging mechanisms for DM1 and DM2 Biochimica et Biophysica Acta (BBA) 2006; 17772:195-204.
50. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293:864-7. (Pubitemid 32743976)
51. Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, Paetau A, et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 2003; 60:1854-7. (Pubitemid 36737094)
52. Fu YH, Friedman DL, Richards S, Pearlman JA, Gibbs RA, Pizzuti A, et al. Decreased expression of myotonin-protein kinase messenger RNA and protein in adult form of myotonic dystrophy. Science 1993; 260:235-8. (Pubitemid 23140893)
53. Jansen G, Groenen PJ, Bachner D, Jap PH, Coerwinkel M, Oerlemans F, et al. Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat Genet 1996; 13:316-24.
54. Berul CI, Maguire CT, Aronovitz MJ, Greenwood J, Miller C, Gehrmann J, et al. DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model. J Clin Invest 1999; 103:1-7.
55. Thornton CA, Wymer JP, Simmons Z, McClain C, Moxley RT, 3rd. Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nat Genet 1997; 16:407-9.
56. Otten AD, Tapscott SJ. Triplet repeat expansion in myotonic dystrophy alters the adjacent chromatin structure. Proc Natl Acad Sci USA 1995; 92:5465-9.
57. Klesert TR, Cho DH, Clark JI, Maylie J, Adelman J, Snider L, et al. Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy. Nat Genet 2000; 25:105-9.
58. Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 1995; 128:995-1002.
59. Davis BM, McCurrach ME, Taneja KL, Singer RH, Housman DE. Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc Natl Acad Sci USA 1997; 94:7388-93.
60. Amack JD, Paguio AP, Mahadevan MS. Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model. Hum Mol Genet 1999; 8:1975-84.
61. Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000; 289:1769-73.
62. Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002; 10:45-53.
63. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002; 10:35-44.
64. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29:40-7.
65. Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans 2009; 37:1281-6.
66. O'Rourke JR, Swanson MS. Mechanisms of RNA-mediated disease. J Biol Chem 2009; 284:7419-23.
67. Napierala M, Krzyzosiak WJ. CUG repeats present in myotonin kinase RNA form metastable "slippery" hairpins. J Biol Chem 1997; 272:31079-85.
68. Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J 2000; 19:4439-48.
69. Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet 2004; 13:3079-88.
70. Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT, et al. Failure of MBNL1-dependent postnatal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006; 15:2087-97.
71. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, et al. A muscleblind knockout model for myotonic dystrophy. Science 2003; 302:1978-80. (Pubitemid 37523508)
72. Kanadia RN, Shin J, Yuan Y, Beattie SG, Wheeler TM, Thornton CA, et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci USA 2006; 103:11748-53. (Pubitemid 44182522)
73. Du H, Cline MS, Osborne RJ, Tuttle DL, Clark TA, Donohue JP, et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol 2010; 17:187-93.
74. Ho TH, Savkur RS, Poulos MG, Mancini MA, Swanson MS, Cooper TA. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci 2005; 118:2923-33.
75. Timchenko LT, Miller JW, Timchenko NA, DeVore DR, Datar KV, Lin L, et al. Identification of a (CUG) n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res 1996; 24:4407-14. (Pubitemid 26388627)
76. Fardaei M, Larkin K, Brook JD, Hamshere MG. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res 2001; 29:2766-71.
77. Mankodi A, Teng-Umnuay P, Krym M, Henderson D, Swanson M, Thornton CA. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol 2003; 54:760-8. (Pubitemid 37498959)
78. Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 2001; 276:7820-6. (Pubitemid 37385575)
79. Mahadevan MS, Yadava RS, Yu Q, Balijepalli S, Frenzel-McCardell CD, Bourne TD, et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 2006; 38:1066-70. (Pubitemid 44325934)
80. Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, Cooper TA. Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci USA 2008; 105:2646-51.
81. Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 2007; 28:68-78.
82. Koshelev M, Sarma S, Price RE, Wehrens XH, Cooper TA. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet 2010; 19:1066-75.
83. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci USA 2008; 105:20333-8.
84. Ho TH, Charlet BN, Poulos MG, Singh G, Swanson MS, Cooper TA. Muscleblind proteins regulate alternative splicing. EMBO J 2004; 23:3103-12. (Pubitemid 39093604)
85. Zhang L, Lee JE, Wilusz J, Wilusz CJ. The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. J Biol Chem 2008; 283:22457-63.
86. Osborne RJ, Lin X, Welle S, Sobczak K, O'Rourke JR, Swanson MS, et al. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet 2009; 18:1471-81.
87. Pandya S, King WM, Tawil R. Facioscapulohumeral dystrophy. Phys Ther 2008; 88:105-13.
88. Shahrizaila N, Wills AJ. Significance of Beevor's sign in facioscapulohumeral dystrophy and other neuromuscular diseases. J Neurol Neurosurg Psychiatry 2005; 76:869-70. (Pubitemid 40805822)
89. van der Maarel SM, Frants RR, Padberg GW. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta 2007; 1772:186-94.
90. Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R, Zatz M. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2004; 14:33-8. (Pubitemid 37494952)
91. Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve 2006; 34:1-15.
92. Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain 1987; 110:631-48.
93. Padberg GW, Brouwer OF, de Keizer RJ, Dijkman G, Wijmenga C, Grote JJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve 1995; 2:73-80.
94. Trevisan CP, Pastorello E, Tomelleri G, Vercelli L, Bruno C, Scapolan S, et al. Facioscapulohumeral muscular dystrophy: hearing loss and other atypical features of patients with large 4q35 deletions. Eur J Neurol 2008; 15:1353-8.
95. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 2004; 63:176-8. (Pubitemid 38943803)
96. Jensen MP, Hoffman AJ, Stoelb BL, Abresch RT, Carter GT, McDonald CM. Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. Arch Phys Med Rehabil 2008; 89:320-8.
97. Kalkman JS, Schillings ML, van der Werf SP, Padberg GW, Zwarts MJ, van Engelen BG, et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I. J Neurol Neurosurg Psychiatry 2005; 76:1406-9.
98. Wijmenga C, Hewitt JE, Sandkuijl LA, Clark LN, Wright TJ, Dauwerse HG, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 1992; 2:26-30.
99. Wijmenga C, van Deutekom JC, Hewitt JE, Padberg GW, van Ommen GJ, Hofker MH, et al. Pulsed-field gel electrophoresis of the D4F104S1 locus reveals the size and the parental origin of the facioscapulohumeral muscular dystrophy (FSHD)-associated deletions. Genomics 1994; 19:21-6. (Pubitemid 24034360)
100. van Deutekom JC, Wijmenga C, van Tienhoven EA, Gruter AM, Hewitt JE, Padberg GW, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 1993; 2:2037-42. (Pubitemid 24003395)
101. Rossi M, Ricci E, Colantoni L, Galluzzi G, Frusciante R, Tonali PA, et al. The Facioscapulohumeral muscular dystrophy region on 4qter and the homologous locus on 10qter evolved independently under different evolutionary pressure. BMC Med Genet 2007; 8:8.
102. de Greef JC, Frants RR, van der Maarel SM. Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. Mutat Res 2008; 647:94-102.
103. Tupler R, Gabellini D. Molecular basis of facioscapulohumeral muscular dystrophy. Cell Mol Life Sci 2004; 61:557-66.
104. Gabellini D, Green MR, Tupler R. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 2002; 110:339-48.
105. Rijkers T, Deidda G, van Koningsbruggen S, van Geel M, Lemmers RJ, van Deutekom JC, et al. FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients. J Med Genet 2004; 41:826-36. (Pubitemid 39524309)
106. Laoudj-Chenivesse D, Carnac G, Bisbal C, Hugon G, Bouillot S, Desnuelle C, et al. Increased levels of adenine nucleotide translocator 1 protein and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle. J Mol Med 2005; 83:216-24. (Pubitemid 40487410)
107. Dixit M, Ansseau E, Tassin A, Winokur S, Shi R, Qian H, et al. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci USA 2007; 104:18157-62. (Pubitemid 350210837)
108. Jiang G, Yang F, van Overveld PG, Vedanarayanan V, van der Maarel S, Ehrlich M. Testing the position-effect variegation hypothesis for facioscapulohumeral muscular dystrophy by analysis of histone modification and gene expression in subtelomeric 4q. Hum Mol Genet 2003; 12:2909-21. (Pubitemid 37442019)
109. Winokur ST, Chen YW, Masny PS, Martin JH, Ehmsen JT, Tapscott SJ, et al. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet 2003; 12:2895-907.
110. Klooster R, Straasheijm K, Shah B, Sowden J, Frants R, Thornton C, et al. Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level. Eur J Hum Genet 2009; 17:1615-24.
111. van Deutekom JC, Lemmers RJ, Grewal PK, van Geel M, Romberg S, Dauwerse HG, et al. Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35. Hum Mol Genet 1996; 5:581-90. (Pubitemid 26141270)
112. Petrov A, Pirozhkova I, Carnac G, Laoudj D, Lipinski M, Vassetzky YS. Chromatin loop domain organization within the 4q35 locus in facioscapulohumeral dystrophy patients versus normal human myoblasts. Proc Natl Acad Sci USA 2006; 103:6982-7.
113. Pirozhkova I, Petrov A, Dmitriev P, Laoudj D, Lipinski M, Vassetzky Y. A functional role for 4qA/B in the structural rearrangement of the 4q35 region and in the regulation of FRG1 and ANT1 in facioscapulohumeral dystrophy. PLoS One 2008; 3:3389.
114. Bodega B, Ramirez GD, Grasser F, Cheli S, Brunelli S, Mora M, et al. Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation. BMC Biol 2009; 7:41.
115. Tupler R, Berardinelli A, Barbierato L, Frants R, Hewitt JE, Lanzi G, et al. Monosomy of distal 4q does not cause facioscapulohumeral muscular dystrophy. J Med Genet 1996; 33:366-70.
116. Gabellini D, D'Antona G, Moggio M, Prelle A, Zecca C, Adami R, et al. Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 2006; 439:973-7.
117. Hanel ML, Wuebbles RD, Jones PL. Muscular dystrophy candidate gene FRG1 is critical for muscle development. Dev Dyn 2009; 238:1502-12.
118. Wuebbles RD, Hanel ML, Jones PL. FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy. Dis Model Mech 2009; 2:267-74.
119. van Koningsbruggen S, Dirks RW, Mommaas AM, Onderwater JJ, Deidda G, Padberg GW, et al. FRG1P is localised in the nucleolus, Cajal bodies and speckles. J Med Genet 2004; 41:46.
120. van Koningsbruggen S, Straasheijm KR, Sterrenburg E, de Graaf N, Dauwerse HG, Frants RR, et al. FRG1P-mediated aggregation of proteins involved in premRNA processing. Chromosoma 2007; 116:53-64.
121. Jurica MS, Licklider LJ, Gygi SR, Grigorieff N, Moore MJ. Purification and characterization of native spliceosomes suitable for three-dimensional structural analysis. Rna 2002; 8:426-39. (Pubitemid 34437714)
122. Makarov EM, Makarova OV, Urlaub H, Gentzel M, Will CL, Wilm M, et al. Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome. Science 2002; 298:2205-8. (Pubitemid 35471248)
123. Rappsilber J, Ryder U, Lamond AI, Mann M. Large-scale proteomic analysis of the human spliceosome. Genome Res 2002; 12:1231-45. (Pubitemid 41264425)
124. Kim SK, Lund J, Kiraly M, Duke K, Jiang M, Stuart JM, et al. A gene expression map for Caenorhabditis elegans. Science 2001; 293:2087-92. (Pubitemid 32848057)
125. Trede NS, Medenbach J, Damianov A, Hung LH, Weber GJ, Paw BH, et al. Network of coregulated spliceosome components revealed by zebrafish mutant in recycling factor p110. Proc Natl Acad Sci USA 2007; 104:6608-13. (Pubitemid 47175548)
126. Licatalosi DD, Darnell RB. Splicing Regulation in Neurologic Disease Neuron 2006; 52:93-101.
127. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998; 18:164-7. (Pubitemid 28082465)
128. Calado A, Tome FM, Brais B, Rouleau GA, Kuhn U, Wahle E, et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 2000; 9:2321-8.
129. Briese M, Esmaeili B, Sattelle DB. Is spinal muscular atrophy the result of defects in motor neuron processes? Bioessays 2005; 27:946-57.
130. Davidovic L, Sacconi S, Bechara EG, Delplace S, Allegra M, Desnuelle C, et al. Alteration of expression of muscle specific isoforms of the fragile X related protein 1 (FXR1P) in facioscapulohumeral muscular dystrophy patients. J Med Genet 2008; 45:679-85.
131. Mientjes EJ, Willemsen R, Kirkpatrick LL, Nieuwenhuizen IM, Hoogeveen-Westerveld M, Verweij M, et al. Fxr1 knockout mice show a striated muscle phenotype: implications for Fxr1p function in vivo. Hum Mol Genet 2004; 13:1291-302. (Pubitemid 38961637)
132. Huot ME, Bisson N, Davidovic L, Mazroui R, Labelle Y, Moss T, et al. The RNA-binding protein fragile X-related 1 regulates somite formation in Xenopus laevis. Mol Biol Cell 2005; 16:4350-61. (Pubitemid 41262902)
133. Van't Padje S, Chaudhry B, Severijnen LA, van der Linde HC, Mientjes EJ, Oostra BA, et al. Reduction in fragile X related 1 protein causes cardiomyopathy and muscular dystrophy in zebrafish. J Exp Biol 2009; 212:2564-70.